$FENC
FENNEC PHARMACEUTICALS INC.

2017 Q3 Form 10-Q Financial Statement

#000114420417058229 Filed on November 13, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2017 Q2 2017 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.690M $1.150M $550.0K
YoY Change 275.56% 101.75% 34.15%
% of Gross Profit
Research & Development $492.0K $333.0K $230.0K
YoY Change 339.29% 139.57% 389.36%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $492.0K $333.0K $770.0K
YoY Change 339.29% 139.57% 1538.3%
Operating Profit -$2.186M -$1.479M
YoY Change 287.59% 109.19%
Interest Expense -$170.0K -$120.0K -$30.00K
YoY Change -950.0% 1100.0% -200.0%
% of Operating Profit
Other Income/Expense, Net -$166.0K -$119.0K -$1.000K
YoY Change -367.74% 600.0% -102.94%
Pretax Income -$2.350M -$1.600M -$810.0K
YoY Change 370.0% 122.22% 92.86%
Income Tax
% Of Pretax Income
Net Earnings -$2.352M -$1.598M -$806.0K
YoY Change 368.53% 120.72% 91.9%
Net Earnings / Revenue
Basic Earnings Per Share -$0.15 -$0.11 -$0.06
Diluted Earnings Per Share -$0.15 -$0.11 -$0.06
COMMON SHARES
Basic Shares Outstanding 15.74M shares 14.19M shares 13.64M shares
Diluted Shares Outstanding 15.74M shares 14.19M shares

Balance Sheet

Concept 2017 Q3 2017 Q2 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.690M $10.23M $3.250M
YoY Change 113.44% 101.38% 490.91%
Cash & Equivalents $9.688M $10.23M $3.251M
Short-Term Investments
Other Short-Term Assets $2.000K $30.00K $40.00K
YoY Change -95.0% 0.0% 0.0%
Inventory
Prepaid Expenses $198.0K
Receivables
Other Receivables
Total Short-Term Assets $9.890M $10.26M $3.290M
YoY Change 115.94% 101.18% 457.63%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets -$2.000K $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $9.890M $10.26M $3.290M
Total Long-Term Assets -$2.000K $0.00 $0.00
Total Assets $9.888M $10.26M $3.290M
YoY Change 115.9% 101.18% 457.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $490.0K $300.0K $220.0K
YoY Change 104.17% -14.29% -4.35%
Accrued Expenses $170.0K $90.00K $130.0K
YoY Change 88.89% 80.0% 62.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.030M $580.0K $430.0K
YoY Change 186.11% 28.89% 22.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.030M $580.0K $430.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.030M $580.0K $430.0K
YoY Change 186.11% 28.89% 22.86%
SHAREHOLDERS EQUITY
Retained Earnings -$119.1M
YoY Change 5.21%
Common Stock $126.7M
YoY Change 9.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.860M $9.679M $2.861M
YoY Change
Total Liabilities & Shareholders Equity $9.888M $10.26M $3.290M
YoY Change 115.9% 101.18% 459.52%

Cashflow Statement

Concept 2017 Q3 2017 Q2 2017 Q1
OPERATING ACTIVITIES
Net Income -$2.352M -$1.598M -$806.0K
YoY Change 368.53% 120.72% 91.9%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$958.0K -$688.0K -$675.0K
YoY Change 76.1% 46.38% 35.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $414.0K $7.669M $0.00
YoY Change 53.07% -100.0%
NET CHANGE
Cash From Operating Activities -$958.0K -$688.0K -$675.0K
Cash From Investing Activities 0.000
Cash From Financing Activities $414.0K $7.669M $0.00
Net Change In Cash -$544.0K $6.981M -$675.0K
YoY Change 0.0% 53.77% 68.75%
FREE CASH FLOW
Cash From Operating Activities -$958.0K -$688.0K -$675.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2017Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
373000 USD
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1030000 USD
CY2017Q3 us-gaap Liabilities
Liabilities
1030000 USD
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
83062000 USD
CY2017Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
43631000 USD
CY2017Q3 us-gaap Revenues
Revenues
0 USD
CY2016Q3 us-gaap Revenues
Revenues
0 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2186000 USD
CY2017Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-183000 USD
CY2016Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
19000 USD
CY2017Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
16000 USD
CY2016Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
3000 USD
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-166000 USD
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
62000 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-502000 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
492000 USD
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
112000 USD
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15740000 shares
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13643000 shares
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15740000 shares
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13643000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12469000 shares
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-119078000 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
244000 USD
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9888000 USD
CY2016Q4 us-gaap Assets
Assets
3972000 USD
CY2017Q3 us-gaap Assets
Assets
9888000 USD
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3000 USD
CY2017Q3 us-gaap Other Assets Current
OtherAssetsCurrent
2000 USD
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
43000 USD
CY2017Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
198000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3926000 USD
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9688000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1050000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
298000 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14533000 shares
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14533000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12469000 shares
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5762000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3595000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
942000 USD
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4537000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8083000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5108000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
248000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-62000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
40000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
512000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
108000 USD
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
155000 USD
CY2017Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
210000 USD
CY2016Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
28000 USD
CY2017Q3 us-gaap Share Based Compensation
ShareBasedCompensation
907000 USD
CY2016Q3 us-gaap Share Based Compensation
ShareBasedCompensation
41000 USD
CY2017Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-958000 USD
CY2016Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-544000 USD
CY2017Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-544000 USD
CY2016Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-544000 USD
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10232000 USD
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5081000 USD
CY2017Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
414000 USD
CY2016Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2017Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
196000 USD
CY2016Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-110000 USD
CY2017Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
71000 USD
CY2016Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
38000 USD
CY2017Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
383000 USD
CY2016Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
CY2017Q3 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-4000 USD
CY2016Q3 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-3000 USD
CY2017Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
31000 USD
CY2016Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
7571000 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
5000000 USD
CY2017Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
9688000 USD
CY2016Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
3926000 USD
CY2017Q3 us-gaap Cash
Cash
440000 USD
CY2016Q4 us-gaap Cash
Cash
51000 USD
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14533000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12469000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15740000 shares
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13643000 shares
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2017Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2016Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0076 pure
CY2016Q4 fencf Stock Options Issuance
StockOptionsIssuance
40000 shares
fencf Stock Options Issuance Exercised
StockOptionsIssuanceExercised
1000 shares
fencf Stock Options Issuance Forfeited
StockOptionsIssuanceForfeited
0 shares
fencf Stock Options Issuance Expired
StockOptionsIssuanceExpired
0 shares
CY2017Q3 fencf Stock Options Issuance
StockOptionsIssuance
39000 shares
CY2016Q4 fencf Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
1.81
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.05
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
CY2017Q3 fencf Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
1.80
CY2017Q2 fencf Stock Options Issuance
StockOptionsIssuance
39000 shares
CY2017Q3 fencf Stock Options Issuance Exercised
StockOptionsIssuanceExercised
0 shares
CY2017Q3 fencf Stock Options Issuance Forfeited
StockOptionsIssuanceForfeited
0 shares
CY2017Q3 fencf Stock Options Issuance Expired
StockOptionsIssuanceExpired
0 shares
CY2017Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1362000 shares
fencf Percentage Of Common Shares Outstanding
PercentageOfCommonSharesOutstanding
0.25 pure
CY2017Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
329000 CAD
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0127 pure
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.36 pure
CY2017Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
21000 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
285000 shares
CY2017Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
9688000 USD
CY2017Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
373000 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
3000 USD
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2016Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15857000 shares
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15857000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13643000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13643000 shares
CY2017Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
CY2016Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
40000 USD
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
40000 USD
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
2861000 USD
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
9679000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-806000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-1598000 USD
CY2017Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
383000 USD
CY2017Q3 fencf Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
31000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Use of estimates</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font>&#160;</div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the interim condensed consolidated financial statements and the reported amounts of expense during the reporting period.&#160;Actual results could differ from those estimates.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In the opinion of management, these unaudited interim condensed consolidated financial statements include all adjustments, which are normal and recurring in nature, necessary for the fair presentation of the Company&#8217;s financial position at September 30, 2017 and to state fairly the results for the periods presented. The most significant estimates utilized during the quarter ended September 30, 2017 included estimates necessary to value derivative instruments, disclosed in Note 4.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q3 us-gaap Cash
Cash
282000 CAD
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0204 pure
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.62 pure
CY2017Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
261000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
326000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
416000 CAD
CY2016Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
324000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
324000 shares
CY2017Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1000 USD
CY2017Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1117000 USD
CY2016Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
50000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1961000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
161000 USD

Files In Submission

Name View Source Status
0001144204-17-058229-index-headers.html Edgar Link pending
0001144204-17-058229-index.html Edgar Link pending
0001144204-17-058229.txt Edgar Link pending
0001144204-17-058229-xbrl.zip Edgar Link pending
fencf-20170930.xml Edgar Link completed
fencf-20170930.xsd Edgar Link pending
fencf-20170930_cal.xml Edgar Link unprocessable
fencf-20170930_def.xml Edgar Link unprocessable
fencf-20170930_lab.xml Edgar Link unprocessable
fencf-20170930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv478748_10q.htm Edgar Link pending
tv478748_10qimg1.jpg Edgar Link pending
tv478748_ex31-1.htm Edgar Link pending
tv478748_ex31-2.htm Edgar Link pending
tv478748_ex32-1.htm Edgar Link pending
tv478748_ex99-1.htm Edgar Link pending
tv478748_ex99-1img1.jpg Edgar Link pending